Formulation Development
Uppsala University Hospital & Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients With Type 1 Diabetes
Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden recently announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to…
Ajinomoto to Acquire Forge Biologics for $620 Million
Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services….
Symbio & Dow Group Merge With Proinnovera to Form Leading Dermatology CRO, Symbio Proinnovera
The newly announced merger of NY-headquartered Symbio LLC and CA-headquartered Dow Development Laboratories LLC with Munster (Germany)-based Proinnovera will form Symbio Proinnovera, creating one of…
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Inc. recently announced its partner in China, Avistone Biotechnology Co. Ltd., received conditional approval from the National Medical Products Administration (NMPA) of China for…
Prange Group & Adragos Pharma to Acquire Fresenius Kabi’s Manufacturing Site
Prange Group and its affiliate Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile pharmaceutical production site in….
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
Mural Oncology plc recently launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop….
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
Evaxion Biotech A/S recently presented for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision…
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases
SciRhom GmbH recently announced the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical Trial Application for its lead…
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human SQ Dosing Option for Patients With Alpha1-Antitrypsin Deficiency
Grifols recently announced it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SQ)…
Absci & Almirall Announce AI Drug Discovery Partnership to Rapidly Develop Novel Treatments for Dermatological Diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases….
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Inc. has signed a non-binding term sheet with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited providing material terms for the acquisition of the company by….
Ocean Biomedical Announces Positive Preclinical Oncology Data for VRON-0300
Ocean Biomedical, Inc. recently announced its joint venture partner, Virion Therapeutics, LLC, recently presented highly compelling preclinical oncology data at the annual meeting of the…
Centogene, University College London & Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early Onset Dystonia & Parkinsonism
Centogene N.V. recently announced the discovery of a new form of early onset dystonia and parkinsonism in the context of neurodevelopmental abnormalities associated to the…
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study
Artax Biopharma, Inc. recently announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to evaluate AX-158 in…
New Issue of Cayman Currents: Lipid Nanoparticles
In Cayman Currents Issue 36, Cayman Chemical showcases the ongoing discoveries and innovation advancing lipid nanoparticles (LNPs) to the forefront of modern medicine and highlights tools available to support LNP research.
Recursion Announces Data Collaboration Deal With Tempus & Updated Focus of Collaboration With Bayer
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio….
BioXcel Therapeutics Reports Positive Overall Survival Results From Single-Arm, Open-Label Phase 2 Trial
BioXcel Therapeutics, Inc. recently announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the company's investigational oral innate immune activator, in…
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic for the Treatment of PTSD
Silo Pharma, Inc. recently announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).…
Qualigen Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial for Treatment of Advanced or Metastatic Solid Tumors
Qualigen Therapeutics, Inc. recently announced the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective…
Yposkesi Launches AAVelocity, a Plug-and-Play AAV Platform
Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), recently launched AAVelocity, a plug-and-play Adeno-Associated Virus (AAV)…
